Brokerages Set Novo Nordisk A/S (NYSE:NVO) Target Price at $53.33

by · The Cerbat Gem

Shares of Novo Nordisk A/S (NYSE:NVO – Get Free Report) have been given a consensus recommendation of “Hold” by the twenty-two analysts that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $53.3333.

NVO has been the topic of a number of recent research reports. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research note on Tuesday, December 23rd. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 3rd. Jefferies Financial Group initiated coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They set an “underperform” rating on the stock. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th.

Read Our Latest Stock Report on NVO

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. raised its position in shares of Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares during the last quarter. Kingstone Capital Partners Texas LLC increased its position in Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after purchasing an additional 10,001,898 shares during the period. Capital International Investors increased its position in Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the period. Boston Partners bought a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $310,199,000. Finally, SG Americas Securities LLC lifted its position in shares of Novo Nordisk A/S by 2,101.5% in the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after purchasing an additional 2,274,925 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

  • Positive Sentiment: FDA approves Wegovy oral pill — a major commercial milestone that opens a new, non‑injectable patient segment and supports a planned U.S. launch in early 2026. This is the key bullish catalyst many investors celebrated. Read More.
  • Positive Sentiment: First‑mover and efficacy edge vs. Lilly’s oral candidate — analysts note Novo may have a head start on oral GLP‑1 market share and trial data show strong weight‑loss results for oral Wegovy, which could help retention vs. competitors. Read More.
  • Neutral Sentiment: Macro/ETF flow tailwinds — FDA nod to an oral GLP‑1 is expected to lift healthcare and obesity‑focused ETFs, bringing incremental investor demand even as company fundamentals are reassessed. Read More.
  • Neutral Sentiment: Short‑term market reaction volatility — coverage notes big share swings after the approval (both big pops and pullbacks) as investors reprice growth expectations for 2026. Read More.
  • Negative Sentiment: Price cuts in China and margin pressure — Novo has cut Wegovy prices in some Chinese provinces and trimmed prices ahead of generic threats, which alongside broader pricing moves could compress margins. Read More. Read More.
  • Negative Sentiment: Margins and investor impatience — commentary warns oral product economics and broader price competition could erode profitability; some analysts flag the risk that oral Wegovy and aggressive pricing will pressure margins and investor patience. Read More.
  • Negative Sentiment: Intense competition from Eli Lilly — Lilly’s tirzepatide franchise and its oral candidate keep competitive pressure high; market share and pricing battles remain key downside risks. Read More. Read More.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $51.19 on Wednesday. The firm’s fifty day moving average price is $49.19 and its two-hundred day moving average price is $56.21. The stock has a market cap of $228.55 billion, a PE ratio of 14.88 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Featured Stories